NEWARK, Del. — According to Future Market Insights (FMI), the global cell-free DNA testing transplant market is valued at USD 466.3 million in 2026 and is projected to reach USD 934.6 million by 2036, expanding at a 7.2% CAGR during the 2026–2036 forecast period. Demand is being supported by transplant programs seeking repeatable blood-based information between routine laboratory surveillance and invasive biopsy decisions. The American Society of Transplant Surgeons stated in October 2024 that kidney programs rely heavily on serum creatinine, urine protein, and donor-specific antibody monitoring, creating a clinical setting in which additional molecular information can support graft-injury assessment.
The market is also shaped by recurring post-transplant surveillance requirements. FMI notes that testing creates commercial value when validated results are incorporated into defined clinical escalation protocols, with purchasing decisions influenced by testing cadence, interpretation, reimbursement, sample logistics, and laboratory responsibilities.
👉 Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends:
https://www.futuremarketinsights.com/reports/sample/rep-gb-34119
Global Segment Leaders
- Kidney Transplant — 31.7% share: Kidney transplantation leads the transplant-type segment in 2026, supported by its large recipient population and established long-term surveillance schedules.
- Next-Generation Sequencing — 36.5% share: NGS leads the technology segment as multiplexed marker coverage supports standardized testing across centralized laboratory networks and established analytical workflows.
- Acute Rejection Monitoring — 36.8% share: This application leads in 2026 because it provides an additional molecular signal during clinically uncertain episodes where physicians are evaluating potential rejection and decisions around further investigation.
- Hospitals — 44.3% share: Hospitals represent the largest end-user category as they coordinate transplant care, laboratory governance, test ordering, and treatment escalation within multidisciplinary teams.
Country-Level Performance
- South Korea – 8.8% CAGR: The Korea National Institute of Health reported in November 2024 that 86 centers participate across five organ cohorts and register more than 2,000 new recipients annually, supporting longitudinal evidence development and protocol comparison.
- Germany – 7.8% CAGR: The German Organ Transplantation Foundation reported 985 deceased donors and 3,020 distributed organs during 2025, supporting recurring molecular surveillance at specialist university hospitals.
- Japan – 7.4% CAGR: Japan’s structured post-transplant reporting system and specialist hospital network support longitudinal recipient follow-up, although local authorization and laboratory governance remain relevant to assay adoption.
- UK – 6.3% CAGR: NHS Blood and Transplant facilitated nearly 4,600 transplants across the United Kingdom during 2024/25, while public commissioning and centralized clinical pathways shape adoption.
- USA – 5.8% CAGR: The Centers for Medicare & Medicaid Services posted the final MolDX LCD notice on July 16, 2026, with the policy scheduled to take effect August 30, 2026, for qualifying for-cause or surveillance uses under organ-specific criteria.
FMI’s country forecasts show a 3.0-percentage-point spread between South Korea and the United States. The report emphasizes that these figures represent modeled market growth rather than current revenue scale, installed testing volume, or legal availability.
👉 Access the Complete Report in PDF Format:
https://www.futuremarketinsights.com/reports/brochure/rep-gb-34119
Regional Context
East Asia contains the fastest-growing profiled market, led by South Korea at 8.8% CAGR, followed by Japan at 7.4%. South Korea benefits from multicenter transplant-cohort infrastructure and concentrated tertiary hospitals, while Japan combines structured recipient follow-up with specialist hospital care.
Europe presents different adoption conditions across Germany and the UK. Germany’s specialist transplantation infrastructure and molecular laboratory capacity support a 7.8% forecast CAGR, while the UK’s centralized transplant system and public commissioning framework underpin a 6.3% CAGR.
North America, represented by the United States in the country-level forecast, is projected to expand at 5.8% CAGR. Established testing networks and coverage routes support adoption, while commercial payer variation and documentation requirements can affect utilization.
FMI’s broader assessment covers North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and the Middle East and Africa, with detailed country forecasts disclosed for the USA, UK, Germany, Japan, and South Korea.
Drivers, Restraints and Opportunities
Recurring transplant surveillance is a central market driver. FMI reports that transplant teams require repeated evidence between routine laboratory changes and biopsy decisions, creating demand for blood-based testing that can be incorporated into established monitoring pathways. CareDx reported in August 2025 that its Kidney Allograft Outcomes AlloSure Registry included 1,743 recipients across 56 U.S. transplant centers, with a testing schedule extending across several years of follow-up.
Clinical interpretation remains a restraint. Donor-derived cell-free DNA can indicate graft injury but does not independently identify every rejection phenotype. FMI notes that transplant teams therefore combine results with graft function, antibody findings, imaging, and biopsy evidence where appropriate.
Decentralized testing creates an opportunity for qualified hospital laboratories. In August 2024, Oncocyte described initial GraftAssure shipments to sites in the United States and Southeast Asia, accompanied by instrument validation and staff training. Local testing can improve control over specimen transport and turnaround, although hospitals assume additional responsibilities for assay validation, equipment maintenance, and proficiency testing.
Competitive Landscape
The competitive landscape includes CareDx, Natera, Eurofins Viracor, Insight Molecular Diagnostics, Devyser Diagnostics, Thermo Fisher Scientific, Bio-Rad Laboratories, and Eurobio Scientific. The companies operate across centralized clinical testing, decentralized assay development, laboratory platforms, and distribution partnerships.
CareDx and Natera provide centralized testing services across multiple transplant indications, while Eurofins Viracor provides TRAC through a specialized reference-laboratory model. Insight Molecular Diagnostics and Devyser pursue decentralized testing through digital PCR and sequencing-based approaches. Thermo Fisher Scientific supports assay distribution through One Lambda, while Bio-Rad provides digital PCR platform support associated with GraftAssure development. Eurobio Scientific commercializes transplant monitoring assay products through laboratory channels outside North America and selected international territories.
Key Recent Developments
- June 2024: Natera launched Donor Quantity Score as a new feature for Prospera Heart, combining donor-derived fraction with absolute donor-derived quantity to support rejection detection across acute cellular and antibody-mediated rejection.
- March 2025: CareDx expanded AlloSure testing to pediatric heart recipients of every age and simultaneous pancreas-kidney recipients. The expanded indications received New York State Clinical Laboratory Evaluation Program approval for clinical testing.
- March 2026: Insight Molecular Diagnostics submitted GraftAssureDx for U.S. Food and Drug Administration review as a kidney transplant rejection testing kit, following ISO 13485 certification and submission of analytical and clinical evidence.
- June 2026: CareDx completed the sale of its Lab Products business to Eurobio Scientific for USD 171.2 million in cash consideration. The transferred business included NGS-based monitoring assays for solid-organ and stem-cell recipients outside North America.
Analyst Perspective
“Clinical adoption will depend on how effectively donor-derived cell-free DNA testing supports transplant decisions within established post-transplant care pathways. Transplant centers are evaluating whether test results improve patient management, reduce unnecessary interventions, and fit reimbursement and laboratory workflows. Companies that strengthen clinical evidence, ensure reliable laboratory support, and demonstrate measurable value across long-term transplant monitoring will be better positioned to expand adoption.”
— Anurag Sharma, Principal Analyst, Future Market Insights
About Future Market Insights
Future Market Insights (FMI) is a leading provider of market research and consulting services, offering syndicated and customized research across industries including healthcare, pharmaceuticals, and biotechnology.
Access Full Report: https://www.futuremarketinsights.com/reports/cell-free-dna-testing-transplant-market
Related Reports:
- Lipoprotein(a) Lowering Therapies Market – https://www.futuremarketinsights.com/reports/lipoprotein-a-lowering-therapies-market
- Neurorehabilitation Technology Market – https://www.futuremarketinsights.com/reports/neurorehabilitation-technology-market
- Organ Transplant Donor-Derived Cell-Free DNA Monitoring Market – https://www.futuremarketinsights.com/reports/organ-transplant-donor-derived-cell-free-dna-monitoring-market
About Future Market Insights (FMI)
Future Market Insights (FMI) is a global market intelligence and consulting firm providing comprehensive market research, competitive intelligence, and strategic business insights across industries. The firm delivers detailed forecasts, technology analysis, and data-driven recommendations that support informed decision-making for manufacturers, investors, distributors, and policymakers worldwide.
For Press & Corporate Inquiries
Rahul Singh
AVP – Marketing and Growth Strategy
Future Market Insights, Inc.
+91 8600020075
For Sales – [email protected]
For Media – [email protected]
For Web – https://www.futuremarketinsights.com
